Related references
Note: Only part of the references are listed.The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review
Mary E. E. Palmer et al.
FRONTIERS IN PHARMACOLOGY (2022)
Pharmacokinetic/Pharmacodynamic Modeling and Application in Antibacterial and Antifungal Pharmacotherapy: A Narrative Review
Laiz Campos Pereira et al.
ANTIBIOTICS-BASEL (2022)
Hope on the Horizon: Novel Fungal Treatments in Development
Adriana M. Rauseo et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review
Anselm Jorda et al.
CLINICAL PHARMACOKINETICS (2020)
Antifungal drugs: What brings the future?
Ruth Van Daele et al.
MEDICAL MYCOLOGY (2019)
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
Lynn Miesel et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
The global problem of antifungal resistance: prevalence, mechanisms, and management
David S. Perlin et al.
LANCET INFECTIOUS DISEASES (2017)
Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections
Kathleen M. Job et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2016)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens et al.
LANCET (2016)
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Francisco M. Marty et al.
LANCET INFECTIOUS DISEASES (2016)
Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model
Seyedmojtaba Seyedmousavi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis
E. P. Garvey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A Phase 2, Randomized, Double-Blind, Multicenter Trial To Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared with Fluconazole in Patients with Uncomplicated Esophageal Candidiasis
J. Viljoen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatus
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Hidden Killers: Human Fungal Infections
Gordon D. Brown et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C-glabrata in a neutropenic murine candidiasis model
D. R. Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
D. Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Anidulafungin versus fluconazole for invasive candidiasis
Annette C. Reboli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2007)
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
PA Warn et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: Importance of persistence of caspofungin in tissues to understanding drug activity
A Louie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2005)
A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis
NTE de Wet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients
N de Wet et al.
CLINICAL INFECTIOUS DISEASES (2004)
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation
JAH van Burik et al.
CLINICAL INFECTIOUS DISEASES (2004)
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia
DS Krause et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: Evidence of concentration-dependent activity
NP Wiederhold et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Randomized, double-blind, Multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases
EG Arathoon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
DW Denning et al.
CLINICAL INFECTIOUS DISEASES (2002)
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis
A Villanueva et al.
CLINICAL INFECTIOUS DISEASES (2001)
In vitro antifungal activity of posaconazole against various pathogenic fungi
K Uchida et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2001)
Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits
AH Groll et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
GK Abruzzo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model
PH Chandrasekar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Is there a need for new antifungal agents?
B de Pauw
CLINICAL MICROBIOLOGY AND INFECTION (2000)
Share Paper
